Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Viracta Therapeutics, Inc. (VIRX) announced the participation of its President and CEO, Mark Rothera, and Chief Medical Officer, Darrel P. Cohen, in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The webcast will be available on the company's website. The company focuses on precision oncology for virus-associated cancers.

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Oppenheimer 34^th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 9:00 a.m. PT/12:00 p.m. ET.

A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" and archived for 90 days.

About Viracta Therapeutics, Inc.
Viracta is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV⁺) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV⁺ nasopharyngeal carcinoma (NPC) and other advanced EBV⁺ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.

For additional information, please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com

SOURCE Viracta Therapeutics, Inc.

FAQ

When is the Oppenheimer 34th Annual Healthcare Life Sciences Conference scheduled?

The conference is scheduled for Tuesday, February 13, 2024, at 9:00 a.m. PT/12:00 p.m. ET.

Who will participate in the virtual fireside chat?

Mark Rothera, President and CEO, and Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer, will participate.

Where can the webcast be accessed?

The webcast will be available on the Investors section of the Viracta website under 'Events and Webcasts' and will be archived for 90 days.

What is the focus of Viracta Therapeutics, Inc.?

The company focuses on the treatment and prevention of virus-associated cancers through precision oncology.